MHRA warning over vision loss as rare side effect linked to weight-loss injection

Credit: coldsnowstorm

By Ella Pickover, PA

The medicines regulator has issued a warning about the rare risk of sudden and painless vision loss linked to a popular weight-loss and diabetes drug.

The Medicines and Healthcare products Regulatory Agency (MHRA) said it had received three reports of non-arteritic anterior ischemic optic neuropathy (NAION) in patients taking semaglutide.